236 related articles for article (PubMed ID: 22545097)
21. Integrin α9β1 promotes malignant tumor growth and metastasis by potentiating epithelial-mesenchymal transition.
Gupta SK; Oommen S; Aubry MC; Williams BP; Vlahakis NE
Oncogene; 2013 Jan; 32(2):141-50. PubMed ID: 22370635
[TBL] [Abstract][Full Text] [Related]
22. Integrin alpha9beta1 directly binds to vascular endothelial growth factor (VEGF)-A and contributes to VEGF-A-induced angiogenesis.
Vlahakis NE; Young BA; Atakilit A; Hawkridge AE; Issaka RB; Boudreau N; Sheppard D
J Biol Chem; 2007 May; 282(20):15187-96. PubMed ID: 17363377
[TBL] [Abstract][Full Text] [Related]
23. Lipopolysaccharide increases the release of VEGF-C that enhances cell motility and promotes lymphangiogenesis and lymphatic metastasis through the TLR4- NF-κB/JNK pathways in colorectal cancer.
Zhu G; Huang Q; Huang Y; Zheng W; Hua J; Yang S; Zhuang J; Wang J; Ye J
Oncotarget; 2016 Nov; 7(45):73711-73724. PubMed ID: 27713159
[TBL] [Abstract][Full Text] [Related]
24. Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients.
Zhao YC; Ni XJ; Li Y; Dai M; Yuan ZX; Zhu YY; Luo CY
World J Surg Oncol; 2012 Aug; 10():165. PubMed ID: 22906075
[TBL] [Abstract][Full Text] [Related]
25. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.
Yang H; Kim C; Kim MJ; Schwendener RA; Alitalo K; Heston W; Kim I; Kim WJ; Koh GY
Mol Cancer; 2011 Apr; 10():36. PubMed ID: 21481239
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor-C and vascular endothelial growth factor-d messenger RNA expression in breast cancer: association with lymph node metastasis.
Koyama Y; Kaneko K; Akazawa K; Kanbayashi C; Kanda T; Hatakeyama K
Clin Breast Cancer; 2003 Dec; 4(5):354-60. PubMed ID: 14715111
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype.
Issa A; Le TX; Shoushtari AN; Shields JD; Swartz MA
Cancer Res; 2009 Jan; 69(1):349-57. PubMed ID: 19118020
[TBL] [Abstract][Full Text] [Related]
28. Fucoxanthin inhibits tumour-related lymphangiogenesis and growth of breast cancer.
Wang J; Ma Y; Yang J; Jin L; Gao Z; Xue L; Hou L; Sui L; Liu J; Zou X
J Cell Mol Med; 2019 Mar; 23(3):2219-2229. PubMed ID: 30648805
[TBL] [Abstract][Full Text] [Related]
29. Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cells.
Mineva ND; Paulson KE; Naber SP; Yee AS; Sonenshein GE
PLoS One; 2013; 8(9):e73464. PubMed ID: 24039951
[TBL] [Abstract][Full Text] [Related]
30. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
[TBL] [Abstract][Full Text] [Related]
31. The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis.
Tutunea-Fatan E; Majumder M; Xin X; Lala PK
Mol Cancer; 2015 Feb; 14():35. PubMed ID: 25744065
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor-D promotes growth, lymphangiogenesis and lymphatic metastasis in gallbladder cancer.
Lin W; Jiang L; Chen Y; She F; Han S; Zhu J; Zhou L; Tang N; Wang X; Li X
Cancer Lett; 2012 Jan; 314(2):127-36. PubMed ID: 22071224
[TBL] [Abstract][Full Text] [Related]
33. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells.
Lee WJ; Chen WK; Wang CJ; Lin WL; Tseng TH
Toxicol Appl Pharmacol; 2008 Jan; 226(2):178-91. PubMed ID: 17961621
[TBL] [Abstract][Full Text] [Related]
34. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer.
Wang CA; Jedlicka P; Patrick AN; Micalizzi DS; Lemmer KC; Deitsch E; Casás-Selves M; Harrell JC; Ford HL
J Clin Invest; 2012 May; 122(5):1895-906. PubMed ID: 22466647
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis.
Eroğlu A; Ersöz C; Karasoy D; Sak S
Adv Clin Exp Med; 2017; 26(2):245-249. PubMed ID: 28791841
[TBL] [Abstract][Full Text] [Related]
36. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma.
Guo B; Zhang Y; Luo G; Li L; Zhang J
Anat Rec (Hoboken); 2009 May; 292(5):633-9. PubMed ID: 19382240
[TBL] [Abstract][Full Text] [Related]
37. The nuclear corepressor 1 and the thyroid hormone receptor β suppress breast tumor lymphangiogenesis.
Martínez-Iglesias O; Olmeda D; Alonso-Merino E; Gómez-Rey S; González-López AM; Luengo E; Soengas MS; Palacios J; Regadera J; Aranda A
Oncotarget; 2016 Nov; 7(48):78971-78984. PubMed ID: 27806339
[TBL] [Abstract][Full Text] [Related]
38. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.
Matsui J; Funahashi Y; Uenaka T; Watanabe T; Tsuruoka A; Asada M
Clin Cancer Res; 2008 Sep; 14(17):5459-65. PubMed ID: 18765537
[TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor A (VEGF-A) induces endothelial and cancer cell migration through direct binding to integrin {alpha}9{beta}1: identification of a specific {alpha}9{beta}1 binding site.
Oommen S; Gupta SK; Vlahakis NE
J Biol Chem; 2011 Jan; 286(2):1083-92. PubMed ID: 21071450
[TBL] [Abstract][Full Text] [Related]
40. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
